Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Work In Process (2022 - 2024)

BioXcel Therapeutics (BTAI) has 3 years of Work In Process data on record, last reported at $387000.0 in Q2 2024.

  • For Q2 2024, Work In Process changed N/A year-over-year to $387000.0; the TTM value through Jun 2024 reached $387000.0, changed N/A, while the annual FY2023 figure was $651000.0, 8.05% down from the prior year.
  • Work In Process reached $387000.0 in Q2 2024 per BTAI's latest filing, up from $253000.0 in the prior quarter.
  • Across five years, Work In Process topped out at $708000.0 in Q4 2022 and bottomed at $122000.0 in Q3 2022.
  • Average Work In Process over 3 years is $447000.0, with a median of $403000.0 recorded in 2022.
  • The widest YoY moves for Work In Process: up 395.9% in 2023, down 8.05% in 2023.
  • A 3-year view of Work In Process shows it stood at $708000.0 in 2022, then fell by 8.05% to $651000.0 in 2023, then tumbled by 40.55% to $387000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Work In Process were $387000.0 in Q2 2024, $253000.0 in Q1 2024, and $651000.0 in Q4 2023.